@article{3d80a61466804c04870d46316db2deb9,
title = "Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11)",
abstract = "Chronic pain is a major source of suffering. It interferes with daily functioning and often is accompanied by distress. Yet, in the International Classification of Diseases, chronic pain diagnoses are not represented systematically. The lack of appropriate codes renders accurate epidemiological investigations difficult and impedes health policy decisions regarding chronic pain such as adequate financing of access to multimodal pain management. In cooperation with the WHO, an IASP Working Group has developed a classification system that is applicable in a wide range of contexts, including pain medicine, primary care, and low-resource environments. Chronic pain is defined as pain that persists or recurs for more than 3 months. In chronic pain syndromes, pain can be the sole or a leading complaint and requires special treatment and care. In conditions such as fibromyalgia or nonspecific low-back pain, chronic pain may be conceived as a disease in its own right; in our proposal, we call this subgroup {"}chronic primary pain.{"} In 6 other subgroups, pain is secondary to an underlying disease: chronic cancer-related pain, chronic neuropathic pain, chronic secondary visceral pain, chronic posttraumatic and postsurgical pain, chronic secondary headache and orofacial pain, and chronic secondary musculoskeletal pain. These conditions are summarized as {"}chronic secondary pain{"} where pain may at least initially be conceived as a symptom. Implementation of these codes in the upcoming 11th edition of International Classification of Diseases will lead to improved classification and diagnostic coding, thereby advancing the recognition of chronic pain as a health condition in its own right.",
keywords = "CHRONIC MUSCULOSKELETAL PAIN, Chronic pain, Chronic primary pain, Chronic secondary pain, Classification, Coding, DAILY-LIFE, DIAGNOSES, Diagnoses, Disease, FEAR, Functioning, GRADING SYSTEM, HEADACHE, ICD-11, IMPACT, MODEL, NEUROPATHIC PAIN, POSTSURGICAL PAIN, PREVALENCE, Symptom",
author = "Rolf-Detlef Treede and Winfried Rief and Antonia Barke and Qasim Aziz and Bennett, {Michael I} and Rafael Benoliel and Milton Cohen and Stefan Evers and Finnerup, {Nanna B} and First, {Michael B} and Giamberardino, {Maria Adele} and Stein Kaasa and Beatrice Korwisi and Eva Kosek and Patricia Lavandʼhomme and Michael Nicholas and Serge Perrot and Joachim Scholz and Stephan Schug and Smith, {Blair H} and Peter Svensson and Vlaeyen, {Johan W S} and Shuu-Jiun Wang",
note = "Funding Information: and personal fees from Berlin Chemie, outside the submitted work. A. Barke reports personal fees from IASP, during the conduct of the study. Q. Aziz reports grants and personal fees from Grunenthal and personal fees from Allergan, outside the submitted work. N.B. Finnerup has received honoraria for serving on advisory boards or speaker panels from Teva, Novartis, Astellas, Gr{\"u}nenthal, Mitshubishe Tanabe, Novartis, and Teva. M. First reports personal fees from Lundbeck International Neuroscience Foundation, outside the submitted work. M.A. Giamberardino reports personal fees from IBSA Institute Bio-chimique, personal fees from EPITECH Group, personal fees from Helsinn Healthcare, grants from EPITECH Group, and grants from Helsinn Healthcare, outside the submitted work. S. Kaasa reports that he is Eir solution—stockholder. J. Scholz has received research support from the Thompson Family Foundation and Acetylon, and is now an employee of Biogen. This work was completed before he joined the company. Biogen did not have a role in the design, conduct, analysis, interpretation, or funding of the research related to this work. S.A. Schug reports that the Discipline of Anaesthesiology and Pain Medicine at the University of Western Australia, but not S.A. Schug personally, has received research and travel funding and speaking and consulting honoraria from Andros Pharmaceuticals, Aspen, bioCSL, Eli Lilly, Grunenthal, Invidior, Janssen, Luye Pharma, Mundipharma, Pfizer, Pierre Fabre, Seqirus and iX Biopharma, outside the submitted work. R. Benoliel, M.I. Bennett, M. Cohen, S. Evers, B. Korwisi, E. Kosek, P. Lavand{\textquoteright}homme, M. Nicholas and S. Perrot, B.H. Smith, P. Svensson, and J.W.S. Vlaeyen have nothing to disclose. Shuu-Jiun Wang reports personal fees from Eli-Lilly, personal fees from Daiichi-Sankyo, grants and personal fees from Pfizer, Taiwan, personal fees from Eisai, personal fees from Bayer, and personal fees from Boehringer Ingelheim, outside the submitted work. Publisher Copyright: {\textcopyright} 2018 The Author(s).",
year = "2019",
month = jan,
doi = "10.1097/j.pain.0000000000001384",
language = "English",
volume = "160",
pages = "19--27",
journal = "Pain",
issn = "0304-3959",
publisher = "Lippincott Williams & Wilkins",
number = "1",
}